What is the added value of FeNO as T2 biomarker?

María Celeste Marcos* and Carolina Cisneros Serrano†

Department of Pulmonology, University Hospital La Princesa, Madrid, Spain

There is increasing evidence about the role of nitric oxide in type 2 (T2) immune response. Fraction of exhaled nitric oxide (FeNO) is a product of airways inflammation and it is increased in patients with asthma. Since Gustaffson published the first article about this biomarker in the 1990s, interest has continued to grow. Compared with other T2 biomarkers such as blood eosinophil count, induced sputum, or serum periostin, FeNO has some remarkable advantages, including its not invasive nature, easy repeatability, and possibility to be performed even in patients with severe airway obstruction. It is considered as an indicator of T2 inflammation and, by the same token, a useful predictor for inhaled steroid response. It is difficult to determine the utility of nitric oxide (NO) for initial asthma diagnosis. In such a heterogenous disease, a single parameter would probably not be enough to provide a complete picture. There is also an important variability among authors concerning FeNO cutoff values and the percentage of sensibility and specificity for diagnosis. Its high specifity indicates a potential role to “rule in” asthma; however, its lower sensibility could suggest a lower capacity to “rule out” this pathology. For this reason, if a diagnosis of asthma is being considered, FeNO should be considered along with other tests. FeNO has also shown its utility to detect response to steroids, adherence to treatment, and risk of exacerbation. Even though there is not enough quality of evidence to establish overall conclusions, FeNO could be an alternative procedure to diagnose or exclude asthma and also a predictive tool in asthma treated with corticosteroids.

KEYWORDS
asthma, biomarker, type 2 immune response, management, fraction of exhaled nitric oxide (FeNO)

Introduction

Asthma is a chronic inflammatory disease, characterized by reversible airway obstruction and bronchial hyperresponsiveness (1). However, in patients with mild asthma, airway obstruction is usually not present, which leads to diagnostic uncertainty. Thus, peak-flow measurement (low diagnostic value) or bronchial provocation (time-consuming, not always available, risk of bronchospasm) has been recommended for such situations (2). Therefore, in recent years, attention is more focused on a promising and simple tool (3).

Based on the degree and type of airway inflammation, a broad-spectrum of phenotypes has been identified (4), some of which have an eosinophilic inflammatory profile, while others may have increased levels of neutrophils. This inflammation, which is difficult to measure in clinical practice, is related to asthma symptoms and exacerbations.
Endogenous nitric oxide is derived from the inducible type of NO synthase (iNOS) present in airway cells including macrophages, neutrophils, epithelial, endothelial, and vascular smooth muscle cells. This enzyme utilizes L-arginine, a semi-essential amino acid, and oxygen as substrates (5). It is produced in response to airway inflammation, with iNOS expression induced by proinflammatory cytokines including tumor necrosis factor-α, interleukin-1b, and interleukin 4 (6, 7). Interleukin 13 (IL-13) may also upregulate the iNOS gene and therefore protein expression in epithelial cells (8).

FeNO has several roles in the regulation of pulmonary function. Thus, increased levels of FeNO in asthma are regarded as indirect markers of airway hyper-responsiveness, eosinophilic inflammation, and also associated with exacerbations and disease severity (9).

Measurement of FeNO concentration in exhaled air is a safe, economical, easy, and non-invasive method. Since Gustaffson (10) published the first article about this biomarker, several techniques have been developed. The chemiluminescence method is the gold standard for exhaled NO analysis (7). There is a highly standardized procedure for the measurement of FeNO. The patient makes an inhalation to total lung capacity and then exhales for 10 s at a specified pressure. According to international guidelines, it has to be done using a mean exhalation flow rate of 50 ml/s and instantaneous flows of 55 ml/s. In healthy adults, FeNO <25 parts per billion (ppb) is considered the normal value (11).

FeNO as a biomarker of airway inflammation

A biomarker is a defined characteristic of a normal or pathogenic biologic process (12). It should be able to distinguish between health and disease, future risk, and response to treatment (13, 14).

Biomarkers such as FeNO, immunoglobulin E (IgE), or blood eosinophil counts are important tools to classify asthma patients into phenotypes. Correlation between biomarker levels and disease severity is limited. However, biomarker-based phenotyping (always associated with clinical evaluation) is important for an adequate characterization of patients and to define the best therapeutic strategy (14).

Although it generally correlates with eosinophilia, FeNO and eosinophilia are related to different type 2 cytokine pathways. Interleukin 5 (IL-5) is involved in the activation, development, and recruitment of eosinophils, while interleukin 4 (IL-4) and IL-13 are implied in IgE synthesis. They are distinct biomarkers for type 2 inflammation. This is the reason why FeNO should be considered a parallel marker of airway inflammation often, but not always, associated with eosinophilia (6). FeNO correlates with type 2 airways inflammation and has shown to be reduced with inhaled corticosteroids (ICS). Conversely, peripheral blood eosinophils originate from systemic circulation and its reduction is more significant with oral corticosteroid treatment (15). Simultaneously, increased blood eosinophil counts and FeNO could be associated with a higher prevalence of uncontrolled asthma: in an observational real-world cross-sectional study (16), patients with higher FeNO levels were characterized by lower body mass index, younger age, higher blood eosinophilia, atopy, higher airflow reversibility, more severe airflow obstruction, as well as persistent rhinitis and chronic rhinosinusitis with or without nasal polyps.

Diagnostic accuracy

The American Thoracic Society (ATS) (11) recommends FeNO as part of the initial diagnosis of asthma. These guidelines define high FeNO levels in adults as >50 ppb, intermediate as 25–50 ppb, and low as <25 ppb. The current National Institute for Health and Care Excellence (NICE) guidelines (17) also propose the use of this tool for the initial diagnosis when asthma is suspected, with a cutoff value >40 ppb to support asthma diagnosis. GEMA (Guía Española para el Manejo del Asma) (4) suggests its utilization if the patient has asthma symptoms, spirometry is within normal limits, and the bronchodilator reversibility test is negative. Diagnosis is confirmed if the patient shows an adequate response to treatment. The BTS (British Thoracic Society) guidelines (18) consider that a positive FeNO test increases the probability of asthma, but a negative test does not exclude asthma. The global strategy for asthma management and prevention (GINA) guidelines (19) do not currently find a role for this biomarker in diagnostic algorithms. Recently, the European Respiratory Society (ERS) Guidelines for the Diagnosis of Asthma in Adults (20) also recommended measuring FeNO in patients suspected of asthma, when the diagnosis could not be established with initial spirometry and bronchodilator reversibility testing. Louis et al. propose a cutoff value of 40 ppb.

It is important to emphasize that regardless of FeNO level, pretest probability of asthma will influence posterior clinical decision-making. Likewise, in spite of pretest probability, a single FeNO measurement should not be interpreted alone (6, 15).

Utility of FeNO for asthma diagnosis is a controversial topic because of the disparity of the results in the accumulating evidence (21). There is an absence of evidence-based, patient-adjusted cutoffs, being one of the pending issues with FeNO measurement (6). Table 1 summarizes the diagnostic accuracy and cutoff values of FeNO.

Predictive factor for exacerbations

Increased levels of FeNO are associated with a higher number of exacerbations. FeNO-guided management showed
a significant reduction in exacerbations of any severity (25, 26). In a real-life study (27), FeNO demonstrated a stronger correlation with asthma exacerbations than peripheral blood eosinophils or periostin with no definite added benefit from a composite score of the three biomarkers. In a study by Busse and colleagues (28), 620 patients with uncontrolled, moderate-to-severe asthma were analyzed. Patients with baseline FeNO of 50 ppb or higher had a 1.54 times higher exacerbation rate than patients with FeNO of less than 25 ppb. Patients with baseline FeNO of 25 to <50 ppb had a 1.33 times higher exacerbation rate than patients with FeNO of less than 25 ppb. Furthermore, when combined with blood eosinophil count, the risk of exacerbation was higher in those with FeNO of 50 ppb or higher and blood eosinophil count of 150 cells per µl or higher (29). In asthmatics treated with inhaled corticosteroids, a low FeNO level could predict a low risk of exacerbation (30). McDowell (31) studied 145 patients with severe eosinophilic asthma in a multicenter observational cohort study. The participants were treated with mepolizumab and exacerbations were assessed. In the group with high sputum eosinophil count, exacerbations were FeNO high (>50 ppb) and with higher blood eosinophil count. On the other hand, the group with low sputum eosinophil count had higher C-reactive protein concentrations, lower FeNO (<20 ppb), and higher sputum neutrophils. FeNO was the most convenient discriminator of inflammatory phenotype at exacerbation.

The asthma guidelines of the Expert Panel Working Group of National Heart, Lung and Blood Institute (NHLBI) do not recommend the use of FeNO in isolation to predict or assess exacerbation frequency (32). This recommendation was likely directed at patients with mild-moderate asthma, in whom FeNO levels were not able to identify those at risk of severe exacerbations (29). Likewise, Pavord (33) studied the effects of as-needed budesonide-formoterol on exacerbations in patients with mild asthma and showed no evidence that FeNO was a prognostic biomarker for exacerbations

**Prediction of response to inhaled corticosteroids**

In steroid-naïve asthma, a high FeNO level could predict a good response to ICS (30, 34).

After a randomized study conducted in 294 patients, Price (35) and cols concluded that treatment with ICS effects was effective for high FeNO: values higher than 50 ppb were associated with greater chances of improvement in cough on the visual analogue scale.

According to ATS guidelines (11), with FeNO values <25 ppb, eosinophilic inflammation and responsiveness to ICS measured by a post-bronchodilator forced expired volume in one second (FEV1) were unlikely, whereas with FeNO values >50 ppb, eosinophilic inflammation and responsiveness to ICS were likely.

Furthermore, low FeNO in asthmatics on regular ICS implies that increasing the glucocorticoid dose would not result in an improvement in the cure of asthma (36, 37).

On the other hand, a single-blind, parallel group, randomized controlled trial in adults using a composite score of T2 biomarkers (38) (including FENO) to adjust corticosteroid dose did not result in a greater proportion of patients reducing corticosteroid dose. FeNO should be used to help the addition of ICS to the treatment but not to suppress them.

However, there is a lack of good-quality data. The predictive ability of FeNO depends on the inflammatory phenotype of asthma; for this reason, the heterogeneity of asthma phenotypes in the mentioned studies could be a confounding factor, diminishing the real clinical benefit of FeNO measurements (30).

**Monitoring ICS adherence**

Persistently high FeNO levels can be an indication of non-adherence. In a study of adult patients with poorly controlled...
asthma (39), FeNO suppression testing was an effective method to detect non-adherence to ICS. Following 1 week on ICS treatment, non-adherent patients experienced a substantial reduction in FeNO levels compared with adherent patients. ATS guidelines (11) suggest that FeNO could assist in the evaluation of adherence to anti-inflammatory medications. Also, NICE guidelines (40) indicate that FeNO is a useful marker for medicine adherence.

**Biological therapy**

As FeNO can reflect the characteristics of the inflammatory profile and whether T2 inflammation may be present, it could be helpful in the selection of biologics for severe asthma (28, 41, 42).

In a large study of patients with severe asthma, Hanania (43) evaluated the benefit of omalizumab on exacerbations in relation to the presence of FeNO and peripheral blood eosinophils. If patients had elevated FeNO (>19.5% ppb), omalizumab reduced exacerbations by 53%, whereas the prevention of exacerbations was 19% when FeNO was <19.5% ppb. In patients treated with omalizumab, FENO ≥19.5 ppb was related to longer time to first exacerbation, reduced exacerbation rate, and improvements in Asthma Quality of Life Questionnaire (AQLQ), compared with those with FENO <19.5 ppb. The ERS/ATS management of severe asthma guidelines (44) advocate using a FENO cutoff ≥19.5 ppb to recognize patients with severe allergic asthma who are more likely to benefit from anti-IgE treatment.

Initial trials (45) with anti-IL-5 and anti-IL-5 receptor antibodies did not show FeNO to be a predictor of response. However, in a post-hoc analysis (46), patients with high baseline blood eosinophil levels experienced a greater reduction in exacerbations on mepolizumab treatment if they also had high baseline FeNO levels. Hoshino (47) combined FeNO and blood eosinophil count in 114 adult patients with type 2 asthma as a strategy to stratify them into 4 subgroups with distinct patterns of airway inflammation and of biologic use. The high-FeNO/high blood eosinophils and the high-FeNO/low blood eosinophils subgroups had the largest frequency of mepolizumab and benralizumab use. The high-FeNO/low blood eosinophils had the highest prevalence of mepolizumab and benralizumab use. The high-FeNO/low blood eosinophils showed the lowest frequency of acute exacerbations (AEs) and the shortest AE-free time in comparison with the other subgroups. This suggests that patients with severe asthma with solely high FeNO levels could be most likely to have refractory type 2 severe asthma.

Castro et al. (48) studied dupilumab in 1,900 patients (LIBERTY ASTHMA QUEST study). Significant dupilumab efficacy was observed in patients with FeNO≥25 ppb or baseline levels of blood eosinophils ≥150 μL⁻¹. Nowadays, dupilumab is the only biologic drug with a therapeutic indication that other treatments do not have yet: FeNO levels are considered within the eligibility criteria. With regard to real-life studies about its effectiveness, Carpagnano et al. (49) demonstrated after 3 months of dupilumab biologic therapy an improvement in asthmatic symptoms (Asthma Control Test ACT pre 13.25 ± 4.65 vs ACT post 19.17 ± 4.45; p < 0.01), FeNO (32 ppb pre vs 19 ppb post) and lung function (FEV1% pre 62.58 ± 15.73 vs FEV1% post 71.00 ± 13.11; p<0.01) in 12 severe type-2 asthma patients, a result that is in line with the multicenter, retrospective, real-world study published by Campisi et al (50). In this other study, patients were treated with dupilumab for 12 months. They observed an interruption of oral corticosteroids in all the patients, an increase in FEV1%, a significant decrease in the number of exacerbations, and an improvement in ACT.

A retrospective analysis of 162 subjects who attended the Difficult Asthma Centres in Belfast and Glasgow and experienced FeNO suppression testing (FeNOSuppT) was performed (51). This test consists in tele-monitoring of inhaler use in conjunction with daily FeNO measurement to identify non-adherence to inhaled corticosteroid (ICS) treatment. This study facilitates profiling for biomarker responses to corticosteroids to detect those patients more likely to respond to high-dose ICS therapy when used regularly and those who, despite good adherence, are likely to require additional treatment. This is the reason why FeNOSuppT could be useful in predicting progression to biologic agents.

Tezepelumab treatment (52, 53) showed a reduction in exacerbation rates and an improvement in lung function with a reduction in FeNO and blood eosinophils. The reduction in annual exacerbations with this biologic therapy was more pronounced with a high-baseline FeNO.

**Cost-effectiveness**

FeNO is a cost-effective method. NICE guidelines (17, 40) concluded that incorporating a combination of peak expiratory flow measurement, spirometry bronchodilator reversibility test, FeNO, and methacholine challenge test was the most cost-effective strategy. Brooks and colleagues (54) reported that FeNO, in conjunction with standard of care guidelines for asthma management, decreased expected per-patient annual expenditure ($2,228) and increased expected per-patient annual quality-adjusted life year (QALY) (0.844) compared with standard of care (SOC) alone ($2,637 and 0.767). In Spain, according to Sabatelli (55), adding FeNO to standard asthma care saved €62,53 euros per patient and year and improved QALY.

**Limitations**

– FeNO levels can also be increased in other conditions such as atopy and can also be affected by many other factors (for
TABLE 2 Factors affecting FeNO levels.

| Increased FeNO          | Decreased FeNO          |
|-------------------------|-------------------------|
| Asthma                  | Smoking                 |
| Asthma                  | Childhood               |
| Atopy                   |                         |
| Atopic dermatitis       |                         |
| Obesity                 |                         |
| Rhinovirus infection    |                         |
| Eosinophilic bronchitis |                         |
| Allergic rhinitis       |                         |
| COPD                    |                         |
| Lung transplant         |                         |

example, smoking reduces FeNO values). This is summarized in Table 2.

FeNO is a marker of type 2 inflammation and therefore it plays less of a role in the diagnosis of non-type 2 asthma.

Currently, GINA guidelines do not include the use of FeNO in their diagnostic pathway.

There are still difficulties in establishing cutoffs for “high” and “low” values.

FeNO testing is often unavailable in primary care, where most asthma diagnoses are made.

Discussion

FeNO is a non-invasive, cheap, and non-time-consuming method. It provides an additional biomarker in the assessment of inflammatory airway diseases. It is accepted that increased FeNO levels are a surrogate of the T2 inflammatory pathway.

This technique can increase diagnostic accuracy in patients with asthma. High values of FeNO in patients with consistent symptoms confirm the suspicion of asthma.

It can be used to identify those patients who are more likely to respond to ICS. High FeNO values are associated with an increased probability of improvement with treatment.

Suppression of FeNO with ICS therapy allows a monitoring of adherence. Non-adherent patients tend to have higher FeNO levels despite the given treatment.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
systematic review. Fractional exhaled nitric oxide for the management of asthma in adults: a meta-analysis of 4,691 participants. Eur Respir J (2015) 8(6):8516–8527. doi: 10.1183/13993003.2015.8.6-8527.

14. Loewenthal L, Menzies-Gow A. FeNO in asthma. Arch Bronconeumol (Engl Ed) 2016; 52(10):529–530.

15. Loewenthal L, Sata R, Ojagenten I, Schleich F, Bonini M, Tonio T, et al. European respiratory society guidelines for the diagnosis of asthma in adults. Respir Med. (2016) 110(10):1585–1595. doi: 10.1016/j.rmed.2016.03.040.

16. Bertolini F, Sprio AE, Baroso A, Riccardi E, Pizzimenti S, Carriero V, et al. Predictors of low and high exhaled nitric oxide values in asthma: a real-world study. Respir Res. (2022) 23(1):744–56. doi: 10.1186/1465-9921-23-744.

17. Asthma. diagnosis and monitoring of asthma in adults, children and young people. London: National Institute for Health and Care Excellence (NICE) (2017). PMID: 29023950.

18. British Thoracic Society/Scottish Intercolligate Guidelines Network. British guidelines on the management of asthma. A national guideline (2016).

19. Global strategy for asthma management and prevention (2021 update).

20. Louis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T, et al. European Respiratory Society guideline. Management of severe asthma: a European Respiratory Society/American Thoracic Society joint task force report. Eur Respir J. (2021) 6(1):57–68. doi: 10.1183/13993003.6016-2020.

21. Ojanguren I, Plaza V. FeNO for asthma diagnosis in adults: more lights than shadows. Arch Bronconeumol (Engl Ed) (2021). 57(2):85–86. English, Spanish. doi: 10.1016/j.arbres.2020.03.035.

22. Whiting FP, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. (2011) 155(8):529–536. doi: 10.7326/0003-4819.155-8.20111080-00009.

23. Li Z, Qin W, Li L, Wu Q, Wang Y. Diagnostic accuracy of exhaled nitric oxide in asthma: a meta-analysis of 4,691 participants. Int J Clin Exp Med. (2015) 8(6):8516–24.

24. Harnan SE, Essat M, Gomersall T, Tappenden P, Pavord I, Everard M, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. –. (2010) 109(3):410–29. doi: 10.1183/09031936.00020407.

25. Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, et al. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. (2018) 6(1):29–39. doi: 10.1016/S2213-2600(17)30442-4.

26. Baptiste AP, Blake KV, Brooks EG, Bryant-Stephens T, et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med. (2020) 8(7):671–80. doi: 10.1016/S2213-2600(20)30047-9.

27. Kuczyk M, Haque S, Middeldorp RJ, Dahlén B, Dahlén SE, BIAAB investigators. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med. (2013) 107(10):1521–30. doi: 10.1016/j.resmed.2013.07.014.

28. Machils A, Baldassarre S, Van Maylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J. (2008) 31(3):539–46. doi: 10.1183/09031936.0002407.

29. Heaney LG, Busby J, Hanratty CE, Dyukanych R, Woodcock A, Walker SM, et al. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. (2018) 6(1):57–68. doi: 10.1016/S2213-2600(18)30397-0. Erratum in: Lancet Respir Med. 2021 Jan 4.

30. Heaney LG, Busby J, Bredding P, Chaudhuri R, Mansur AH, Niven R, et al. Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. (2019) 199(4):454–64. doi: 10.1164/ rccm.201811-1820OC.

31. Holguin F, Cardet JC, Chung KF, Diver S, Ferrerse DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. (2020) 55(1):1900588. doi: 10.1183/ 13993003.00588-2019.

32. Holguin F, Cardet JC, Chung KF, Diver S, Ferrerse DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. (2020) 55(1):1900588. doi: 10.1183/ 13993003.00588-2019.

33. Holguin F, Cardet JC, Chung KF, Diver S, Ferrerse DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. (2020) 55(1):1900588. doi: 10.1183/ 13993003.00588-2019.
nitric oxide and low blood eosinophil counts. Front Pharmacol. (2022) 13:836635. doi: 10.3389/fphar.2022.836635

48. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe K, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. (2018) 378:2486–96. doi: 10.1056/NEJMoa1804092

49. Carpagnano GE, Scioscia G, Buonamico E, Lacedonia D, Diaferia F, Capozza E, et al. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting: a FeNO-driven choice that leads to winning management. Multidiscip Respir Med. (2022) 17(1):797. doi: 10.4081/mrm.2022.797

50. Campisi R, Crimi C, Nolasco S, Beghè B, Antonicelli L, Guarnieri G, et al. Real-World experience with dupilumab in severe asthma: one-year data from an Italian named patient program. J Asthma Allergy. (2021) 14:575–83. doi: 10.2147/JAA.S312123

51. Butler CA, McMichael AJ, Honeyford K, Wright L, Logan J, Holmes J, et al. Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy. ERJ Open Res. (2021) 7(3):00273–2021. doi. 10.1183/23120541.00273-2021

52. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. (2021) 384(19):1800–9. doi: 10.1056/NEJMoa2034975

53. Corren J, Barnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. (2017) 377(10):936–46. doi: 10.1056/NEJMoa1704064. Erratum in: N Engl J Med. 2019 May 23;380(21):2082.

54. Brooks EA, Massanari M. Cost-Effectiveness analysis of monitoring fractional exhaled nitric oxide (FeNO) in the management of asthma. Manag Care. (2018) 27(7):42–8. PMID: 29989901

55. Sabatelli L, Seppälä U, Sastre J, Crater G. Cost-effectiveness and budget impact of routine use of fractional exhaled nitric oxide monitoring for the management of adult asthma patients in Spain. J Investig Allergol Clin Immunol. (2017) 27(2):89–97. doi: 10.18176/jiaci.0103